E-LIB Suche - Ergebnisse für: Tillman, Erik

1

LBO-002 Efruxifermin significantly reduced liver fibrosis i..:

Harrison, Stephen A. ; Frias, Juan P ; Neff, Guy...
Journal of Hepatology. 80 (2024) - p. S8 , 2024

Link: https://doi.org/10.1016/..

2

Safety and Efficacy of Efruxifermin in Combination With a G..:

Harrison, Stephen A. ; Frias, Juan P. ; Lucas, K. Jean...
Clinical Gastroenterology and Hepatology. , 2024

Link: https://doi.org/10.1016/..

3

SAT-220-YI Efruxifermin treatment improved collagen biomark..:

Tillman, Erik ; Chan, Doreen ; Shringarpure, Reshma...
Journal of Hepatology. 80 (2024) - p. S612-S613 , 2024

Link: https://doi.org/10.1016/..

4

A randomized, double-blind, placebo-controlled phase IIa tr..:

Harrison, Stephen A. ; Ruane, Peter J. ; Freilich, Bradley...
JHEP Reports. 5 (2023) 1 - p. 100563 , 2023

Link: https://doi.org/10.1016/..

5

Noncompetitive immunoassay optimized for pharmacokinetic as..:

Kinne, Adam S. ; Tillman, Erik J. ; Abdeen, Sanofar J....
Journal of Pharmaceutical and Biomedical Analysis. 232 (2023) - p. 115402 , 2023

Link: https://doi.org/10.1016/..

6

Non-invasive tests of liver injury, inflammation and fibros..:

Schattenberg, Jörn ; Frias, Juan P ; Neff, Guy...
Journal of Hepatology. 78 (2023) - p. S808-S809 , 2023

Link: https://doi.org/10.1016/..

7

Characterization of the patterns of resolution of histopath..:

Behling, Cynthia ; Bedossa, Pierre ; Shao, Lan...
Journal of Hepatology. 78 (2023) - p. S820-S821 , 2023

Link: https://doi.org/10.1016/..

8

ODP178 Development and Validation of a Noncompetitive Immun..:

Hurst, Jacob ; Johnson, Derrick ; Tillman, Erik...
Journal of the Endocrine Society. 6 (2022) Supplement_1 - p. A304-A305 , 2022

Link: https://doi.org/10.1210/..

9

Efx treatment improved histopathology and non-invasive mark..:

Tillman, Erik ; Shringarpure, Reshma ; Neff, Guy...
Journal of Hepatology. 77 (2022) - p. S719 , 2022

Link: https://doi.org/10.1016/..

10

Efruxifermin, a long‐acting Fc‐fusion FGF21 analogue, reduc..:

Tillman, Erik J. ; Brock, William J. ; Rolph, Tim
British Journal of Pharmacology. 179 (2022) 7 - p. 1384-1394 , 2022

Link: https://doi.org/10.1111/..

11

Efruxifermin in non-alcoholic steatohepatitis: a randomized..:

Harrison, Stephen A. ; Ruane, Peter J. ; Freilich, Bradley L....
Nature Medicine. 27 (2021) 7 - p. 1262-1271 , 2021

Link: https://doi.org/10.1038/..

12

Generation of Affinity Purified Antibody Reagents for Speci..:

Kinne, Adam S ; Abdeen, Sanofar J ; Parmer, Elijah S...
Journal of the Endocrine Society. 5 (2021) Supplement_1 - p. A288-A288 , 2021

Link: https://doi.org/10.1210/..

13

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Ste..:

Tillman, Erik J. ; Rolph, Tim
Frontiers in Endocrinology. 11 (2020) - p. , 2020

Link: https://doi.org/10.3389/..

14

AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynam..:

Kaufman, Allegra ; Abuqayyas, Lubna ; Denney, William S...
Cell Reports Medicine. 1 (2020) 4 - p. 100057 , 2020

Link: https://doi.org/10.1016/..

15

AKR-001, an engineered Fc-FGF21 variant, directly modulates..:

Tillman, Erik ; Kijanska, Monika ; Rolph, Tim
Journal of Hepatology. 73 (2020) - p. S660-S661 , 2020

Link: https://doi.org/10.1016/..